Recursion Pharmaceuticals, Inc.

NasdaqGS:RXRX Voorraadrapport

Marktkapitalisatie: US$1.8b

Recursion Pharmaceuticals Toekomstige groei

Future criteriumcontroles 2/6

De winst van Recursion Pharmaceuticals zal naar verwachting dalen met 1.9% per jaar, terwijl de jaarlijkse omzet naar verwachting zal groeien met 23% per jaar. De winst per aandeel zal naar verwachting groeien met 10.3% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting -168.1% zijn.

Belangrijke informatie

-1.9%

Groei van de winst

10.3%

Groei van de winst per aandeel

Biotechs winstgroei27.3%
Inkomstengroei23.0%
Toekomstig rendement op eigen vermogen-168.1%
Dekking van analisten

Good

Laatst bijgewerkt07 Oct 2024

Recente toekomstige groei-updates

Earnings Beat: Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Aug 12
Earnings Beat: Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

May 12
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

Recent updates

Recursion: AI Is Only As Good As The Data

Sep 11

Recursion: Path Forward For REC-994 Remains Despite Mixed Response

Sep 04

Earnings Beat: Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Aug 12
Earnings Beat: Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Recursion Pharmaceuticals: AI-Driven 'TechBio' With Upcoming Catalysts

Aug 01

Recursion Pharmaceuticals: More Of A TechBio Industrializing Drug Discovery

Jun 24

Recursion Pharmaceuticals: Catalysts Are Coming And Success Is A Must

Jun 14

Revenues Not Telling The Story For Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) After Shares Rise 25%

May 22
Revenues Not Telling The Story For Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) After Shares Rise 25%

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

May 12
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

Revisiting Recursion: Big Bets, Big Data, And The Big Cash Burn Rate

Apr 10

Recursion: Exercising Caution Prior To Q3 Data Release (Rating Downgrade)

Mar 20

Recursion Pharmaceuticals (NASDAQ:RXRX) Is Using Debt Safely

Jan 31
Recursion Pharmaceuticals (NASDAQ:RXRX) Is Using Debt Safely

Recursion Pharmaceuticals: More Hype Than Substance Amid Signs Of Progress

Jan 12

Recursion Pharmaceuticals, Inc.'s (NASDAQ:RXRX) 45% Price Boost Is Out Of Tune With Revenues

Dec 09
Recursion Pharmaceuticals, Inc.'s (NASDAQ:RXRX) 45% Price Boost Is Out Of Tune With Revenues

What You Need To Know About The Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Analyst Downgrade Today

May 09
What You Need To Know About The Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Analyst Downgrade Today

We Think Recursion Pharmaceuticals (NASDAQ:RXRX) Can Easily Afford To Drive Business Growth

Mar 01
We Think Recursion Pharmaceuticals (NASDAQ:RXRX) Can Easily Afford To Drive Business Growth

Winst- en omzetgroeiprognoses

NasdaqGS:RXRX - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
12/31/2026104-380-221-2705
12/31/202563-465-365-3378
12/31/202469-397-311-2989
6/30/202450-375-346-332N/A
3/31/202446-354-331-317N/A
12/31/202345-328-300-288N/A
9/30/202347-293-277-258N/A
6/30/202350-260-266-240N/A
3/31/202347-249-273-234N/A
12/31/202240-239-121-84N/A
9/30/202229-247-134-100N/A
6/30/202218-234-113-78N/A
3/31/202213-212-75-50N/A
12/31/202110-186-198-159N/A
9/30/202110-147-129-89N/A
6/30/20219-124-106-75N/A
3/31/20216-99-84-58N/A
12/31/20204-87-52-45N/A
12/31/20192-62-61-57N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat RXRX de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat RXRX de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat RXRX de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van RXRX ( 23% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.8% per jaar).

Hoge groei-inkomsten: De omzet van RXRX ( 23% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.


Groeiprognoses winst per aandeel


Toekomstig rendement op eigen vermogen

Toekomstige ROE: Er wordt voorspeld dat RXRX binnen 3 jaar verliesgevend zal zijn.


Ontdek groeibedrijven